Table 2.
Associated with VR-CHOP n (%) of eligible patients (total n = 65) | Associated with bortezomib maintenance n (%) of eligible patients (total n = 47) | |||||
---|---|---|---|---|---|---|
Adverse Event (grade ≥3) | Grade 3 | Grade 4 | Grade 5 | Grade 3 | Grade 4 | Grade 5 |
Hematologic/infection | ||||||
Neutropenia | 9 (14) | 25 (38) | - | - | - | - |
Febrile neutropenia | 11 (17) | 1 (2) | - | - | - | - |
Thrombocytopenia | 5 (8) | 6 (9) | - | - | - | - |
Anemia | 3 (5) | - | - | - | - | - |
Lymphopenia | 11 (17) | 4 (6) | - | 1 (2) | 1 (2) | - |
Leukopenia | 16 (25) | 10 (15) | - | - | - | - |
Lung infection | 4 (6) | - | - | 1 (2) | - | - |
Cardiovascular | - | - | 1 (2) | - | - | - |
Diarrhea | 3 (5) | - | - | - | - | - |
Fatigue | 4 (6) | 2 (3) | - | 1 (2) | - | - |
Hyperglycemia | 3 (5) | - | - | - | - | - |
Hyperuricemia | - | 1 (2) | - | - | - | - |
Sensory neuropathy | 3 (5) | - | - | 1 (2) | - | - |